Therapeutic complement inhibition: new developments
Activation of the complement system significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases. Current strategies to inhibit complement include the replacement or substitution of endogenous soluble complement inhibitors (e.g., C1 inhibitor [C1 inh], recombinant...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2010
|
| In: |
Seminars in thrombosis and hemostasis
Year: 2010, Jahrgang: 36, Heft: 6, Pages: 660-668 |
| ISSN: | 1098-9064 |
| DOI: | 10.1055/s-0030-1262888 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: http://dx.doi.org/10.1055/s-0030-1262888 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0030-1262888 
|
| Verfasserangaben: | Woodruff Emlen, Wenhan Li, and Michael Kirschfink |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1760793000 | ||
| 003 | DE-627 | ||
| 005 | 20220819233725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210618s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0030-1262888 |2 doi | |
| 035 | |a (DE-627)1760793000 | ||
| 035 | |a (DE-599)KXP1760793000 | ||
| 035 | |a (OCoLC)1341416532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Emlen, Woodruff |e VerfasserIn |0 (DE-588)1235761894 |0 (DE-627)1760797383 |4 aut | |
| 245 | 1 | 0 | |a Therapeutic complement inhibition |b new developments |c Woodruff Emlen, Wenhan Li, and Michael Kirschfink |
| 264 | 1 | |c 2010 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.06.2021 | ||
| 520 | |a Activation of the complement system significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases. Current strategies to inhibit complement include the replacement or substitution of endogenous soluble complement inhibitors (e.g., C1 inhibitor [C1 inh], recombinant soluble complement receptor 1, TP10), the administration of antibodies to block key proteins of the cascade reaction (e.g., C5) or to neutralize the action of the complement-derived anaphylatoxins, or blockade of complement receptors (e.g., C5aR, CD88). The recent approvals of anti-C5 for the treatment of paroxysmal nocturnal hemoglobinuria as well as of C1 inh for the treatment of hereditary angioedema beyond European countries have provided a resurgence of interest in the potential of complement therapeutics for the treatment of disease. | ||
| 650 | 4 | |a Angioedemas, Hereditary | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Antibodies, Monoclonal | |
| 650 | 4 | |a Complement Activation | |
| 650 | 4 | |a Complement C1 Inhibitor Protein | |
| 650 | 4 | |a Complement Pathway, Alternative | |
| 650 | 4 | |a Complement System Proteins | |
| 650 | 4 | |a Humans | |
| 700 | 1 | |a Li, Wenhan |e VerfasserIn |0 (DE-588)1171954077 |0 (DE-627)1040821227 |0 (DE-576)513934111 |4 aut | |
| 700 | 1 | |a Kirschfink, Michael |e VerfasserIn |0 (DE-588)120927152 |0 (DE-627)080974457 |0 (DE-576)292452411 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in thrombosis and hemostasis |d New York, NY : Thieme, 1974 |g 36(2010), 6, Seite 660-668 |h Online-Ressource |w (DE-627)342892754 |w (DE-600)2072469-X |w (DE-576)279447868 |x 1098-9064 |7 nnas |a Therapeutic complement inhibition new developments |
| 773 | 1 | 8 | |g volume:36 |g year:2010 |g number:6 |g pages:660-668 |g extent:9 |a Therapeutic complement inhibition new developments |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0030-1262888 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.thieme-connect.de/DOI/DOI?10.1055/s-0030-1262888 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210618 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 120927152 |a Kirschfink, Michael |m 120927152:Kirschfink, Michael |d 910000 |d 911600 |e 910000PK120927152 |e 911600PK120927152 |k 0/910000/ |k 1/910000/911600/ |p 3 |y j | ||
| 998 | |g 1171954077 |a Li, Wenhan |m 1171954077:Li, Wenhan |d 910000 |d 911600 |e 910000PL1171954077 |e 911600PL1171954077 |k 0/910000/ |k 1/910000/911600/ |p 2 | ||
| 999 | |a KXP-PPN1760793000 |e 3939373257 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1055/s-0030-1262888"],"eki":["1760793000"]},"origin":[{"dateIssuedDisp":"2010","dateIssuedKey":"2010"}],"name":{"displayForm":["Woodruff Emlen, Wenhan Li, and Michael Kirschfink"]},"relHost":[{"part":{"year":"2010","pages":"660-668","issue":"6","text":"36(2010), 6, Seite 660-668","volume":"36","extent":"9"},"pubHistory":["Nachgewiesen 1.1974,2 -"],"recId":"342892754","language":["eng"],"note":["Gesehen am 07.11.2013"],"disp":"Therapeutic complement inhibition new developmentsSeminars in thrombosis and hemostasis","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Seminars in thrombosis and hemostasis","title":"Seminars in thrombosis and hemostasis"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1098-9064"],"doi":["10.1055/s-00000077"],"eki":["342892754"],"zdb":["2072469-X"]},"origin":[{"publisherPlace":"New York, NY ; Stuttgart","publisher":"Thieme","dateIssuedKey":"1974","dateIssuedDisp":"1974-"}]}],"physDesc":[{"extent":"9 S."}],"title":[{"title":"Therapeutic complement inhibition","subtitle":"new developments","title_sort":"Therapeutic complement inhibition"}],"person":[{"family":"Emlen","given":"Woodruff","display":"Emlen, Woodruff","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Li","given":"Wenhan","roleDisplay":"VerfasserIn","display":"Li, Wenhan","role":"aut"},{"family":"Kirschfink","given":"Michael","display":"Kirschfink, Michael","roleDisplay":"VerfasserIn","role":"aut"}],"language":["eng"],"recId":"1760793000","note":["Gesehen am 18.06.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a EMLENWOODRTHERAPEUTI2010 | ||